Hmm I would answer that by the fact that it reduces the pain and function and due to its inherent action and durability these levels stay low for some time. That's the ace durability of the drug.
At the end of the day you want efficiency (as well as efficacy)....as little drug as possible for max effect....ie as statistically relevant as possible.
Patients would much rather an initial course and then boosters once a year...rather than monthly ongoing injections, even if these are self administered SubQ.
This is the goal, this is the beauty of what we have.
My opinions.
research reports and media, page-2055
-
- There are more pages in this discussion • 2,397 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
-0.005(2.04%) |
Mkt cap ! $83.98M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 24.0¢ | $202.2K | 814.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 181098 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 118621 | 5 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |